Not content to just put out one twisty movie at the holiday season with Wake Up Dead Man, Netflix decided to open the floodgates – pun fully intended – with South Korean disaster movie The Great Flood ...

The first season of HBO's It: Welcome to Derry has come to a close, leaving us with a long list of questions that need to somehow be answered when the show leaps back in time another 27 years for ...

Are you a multitasker, a free spirit, or an overly optimistic planner? Experts say these are some of the traits that explain why some people are always running behind. Some people just seem wired to ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Volume 1 of the final season of "Stranger Things" is now out, and it's left viewers with a bunch of burning questions. In this article explaining the ending of Stranger Things Season 5, you’ll find ...

SPOILER ALERT: This story contains spoilers from Season 5, Volume 1 of “Stranger Things.” In the battle that concludes Volume 1 of “Stranger Things 5” — in “Sorcerer,” written and directed by Matt and ...

This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Transaction value is based on the SEC Form 4 weighted average purchase price ($6.04) as reported for the transaction on October 10, 2025. How does the scale of this transaction compare to Christopher ...